mailed
on 21 Mar 2024
Last Applicant/ Owned by
55 Cambridge Parkway, Suite 800E
Cambridge
MA
02142
Serial Number
98278615 filed on 20th Nov 2023
Registration Number
N/A
Correspondent Address
Christina M. Licursi
Filing Basis
1. intent to use
2. intent to use current
Disclaimer
NO DATA
Pharmaceutical preparations for the treatment and prevention of cancer, cardiovascular diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, genetic and genomic diseases and disorders, immunological diseases and disorders, metabolic diseases and disorders, endocrine diseases and disorders, kidney diseases and disorders, dermatological diseases and dis Read More
Pharmaceutical preparations for the treatment and prevention of cancer, cardiovascular diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, genetic and genomic diseases and disorders, immunological diseases and disorders, metabolic diseases and disorders, endocrine diseases and disorders, kidney diseases and disorders, dermatological diseases and disorders, reproductive diseases and disorders, urological diseases and disorders, allergies, bone diseases and disorders, diseases and disorders of the musculo-skeletal and genitourinary systems, and viruses and infectious diseases; therapeutic pharmaceutical for the treatment and prevention of cancer, cardiovascular diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, genetic and genomic diseases and disorders, immunological diseases and disorders, metabolic diseases and disorders, endocrine diseases and disorders, kidney diseases and disorders, dermatological diseases and disorders, reproductive diseases and disorders, urological diseases and disorders, allergies, bone diseases and disorders, diseases and disorders of the musculo-skeletal and genitourinary systems, and viruses and infectious diseases; pharmaceutical compositions comprised of small molecules for the treatment and prevention of cancer, cardiovascular diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, genetic and genomic diseases and disorders, immunological diseases and disorders, metabolic diseases and disorders, endocrine diseases and disorders, kidney diseases and disorders, dermatological diseases and disorders, reproductive diseases and disorders, urological diseases and disorders, allergies, bone diseases and disorders, diseases and disorders of the musculo-skeletal and genitourinary systems, and viruses and infectious diseases; pharmaceutical preparations, namely, DNA therapeutics for the treatment and prevention of cancer, cardiovascular diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, genetic and genomic diseases and disorders, immunological diseases and disorders, metabolic diseases and disorders, endocrine diseases and disorders, kidney diseases and disorders, dermatological diseases and disorders, reproductive diseases and disorders, urological diseases and disorders, allergies, bone diseases and disorders, diseases and disorders of the musculo-skeletal and genitourinary systems, and viruses and infectious diseases; pharmaceutical preparations, namely, RNA therapeutics for the treatment and prevention of cancer, cardiovascular diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, genetic and genomic diseases and disorders, immunological diseases and disorders, metabolic diseases and disorders, endocrine diseases and disorders, kidney diseases and disorders, dermatological diseases and disorders, reproductive diseases and disorders, urological diseases and disorders, allergies, bone diseases and disorders, diseases and disorders of the musculo-skeletal and genitourinary systems, and viruses and infectious diseases
N/A
N/A
No 98278615
No Service/Collective Mark
No F09042000200
No
No
No
No
No
No
No
No
Status Date | Action Taken |
---|---|
21st Mar 2024 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED |
21st Mar 2024 | LETTER OF SUSPENSION E-MAILED |
21st Mar 2024 | SUSPENSION LETTER WRITTEN |
19th Mar 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
19th Mar 2024 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
19th Mar 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
26th Feb 2024 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
26th Feb 2024 | NON-FINAL ACTION E-MAILED |
26th Feb 2024 | NON-FINAL ACTION WRITTEN |
20th Feb 2024 | ASSIGNED TO EXAMINER |